Multiorgan toxicity due to ecstasy abuse

Key Findings & Data:Problems in central and periferic nerveous systems, renal and hepatic failure, electrolite imbalance and hyperthermia may develop after ecstasy abuse.

💡

Conclusion & Impact:In this report, we consulted a case with renal failure, hepatic failure and peripheral neuropathy derived from ecstasy

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Periferik sinir sistemi hastalıkları · N-metil-3 · 4-metilendioksiamfetamin

Abstract

The frequency of ecstasy abuse has been increasing in the world especially in developed countries. Problems in central and periferic nerveous systems, renal and hepatic failure, electrolite imbalance and hyperthermia may develop after ecstasy abuse. In this report, we consulted a case with renal failure, hepatic failure and peripheral neuropathy derived from ecstasy

Özet

Dünyada gelişmiş ülkelerdeki toplumlarda ecstasy kullanım sıklığı artmaktadır. Ecstasy kullanımı sonucunda santral ve periferik sinir sisteminde problemler, sıvı-elektrolit dengesizlikleri, hipetermi, karaciğer ve böbrek yetmezliği gelişebilmektedir. Bu yazımızda kliniğimizde ecstasy kullanımı sonucunda akut karaciğer yetmezliği, akut böbrek yetmezliği, periferik nöropati gelişen bir olguyu tartıştık.

Keywords

Periferik sinir sistemi hastalıkları N-metil-3 4-metilendioksiamfetamin İlaç toksisitesi Madde bağımlılığı bozuklukları Böbrek yetmezliği Karaciğer yetmezliği Peripheral Nervous System Diseases N-Methyl-3 4-methylenedioxyamphetamine Drug Toxicity Substance-Related Disorders Kidney Failure Liver Failure

🔖

Cite This Article

ÇAĞLAR, U., PİLANCI, A., KÜÇÜKŞAHİN, O., SOYSAL, D., KAPLAN, Y. C. (2005). Multiorgan toxicity due to ecstasy abuse. Medical Network Klinik Bilimler ve Doktor, Cilt: 11 - Sayı: 2, 132–134. https://ajindex.com/articles/278425

References (1)

Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999; 13:129-33 2.Greene SL, Dargan PI, O'Connor N, et al. Multiple toxicitiy from 3,4-Methylenedioxymethamphetamine (Ecstasy). Am J Emerg Med. 2003; 21:121-4. 3.Ajaelo I, Koenig K, Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use (letter). Acad Emerg Med 1998; 5:839-40. 4.Barrett PJ, Taylor GT. Ecstasy ingestion: a case report of severe complications. J Roy Soc Med 1993; 86:233-4. 5.Abraham RB, Szold O, Rudick V, Weinbroum AA. 'Ecstasy' intoxication: life -threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med 2003; 10:309-13. 6.Vastag B. Ecstasy experts want realistic messages. JAMA 2001; 286:777. 7.Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (Ecstasy). Lancet 1992; 340:384-7. 8.Schmidt CJ, Taylor VL, Abbate GM, et al. 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4 methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa: J Pharmacol Exp Ther 1991; 38:339-44. 9.Fahal IH, Sallomi, Yaqoob M, Bell GM. Acute renal failure after ecstasy.BMJ 1992; 305:29. 10.Foley RJ, Kapatkin K, Verani R, Weinman EJ. Amphetamine induced acute renal failure.South Med J 1984; 77:258-60. 11.Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996; 38:454-8. 12.Kew M, Bersohn I, Seftel H, Kent G. Liver damage in heat stroke. Am J M 1970; 49:192-202. 13.Chadwick IS, Curry PD, Linsley A, et al. Ecstasy, 3-4-methylenedioxymethamphetamine (MDMA), a fatalitiy associated with coagulopathy and hyperthermia. J R Soc Med 1991; 84:371. 14.Reneman L, Booij J, Majoie CB, Van Den Brink W, Den Heeten GJ. Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. Hum Psychopharmacol 2001; 16:579-88. 15.Reneman L. Designer drugs: how dangerous are they? J Neural Transm Suppl. 2003; 66:61-83. 16.Jacobsen LK, Mend WE, Pugh KR, Skudlarski P, Krystal JH. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology 2004; 173:383-90. 17.Shibolet O, Kalish Y, Gillis S, İlan Y. Hepatic and hemotological complications following ecstasy usage. Harefuah. 2001; 140:911-4.